Table 2.
Logistic regression analysis of the association between moderate-to-severe hepatosteatosis and clinical variables.
| Variable | Crude | Adjusted | ||
|---|---|---|---|---|
| OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
| Age years | ||||
| <65 | Ref. | Ref. | ||
| ⩾65 | 0.66 (0.48–0.89) | 0.007 | 0.57 (0.39–0.84) | 0.004 |
| Sex | ||||
| Male | Ref. | Ref. | ||
| Female | 1.01 (0.75–1.37) | 0.938 | 1.68 (1.10–2.58) | 0.016 |
| WHR | 3.48 (2.61–4.65) | <0.001 | 3.08 (2.17–4.38) | <0.001 |
| Laboratory data | ||||
| Uric acid | 1.56 (1.27–1.91) | <0.001 | 1.36 (1.05–1.77) | 0.018 |
| TG | 1.74 (1.48–2.05) | <0.001 | 1.27 (1.05–1.54) | 0.013 |
| HDL | 0.57 (0.45–0.72) | <0.001 | 0.80 (0.59–1.09) | 0.164 |
| Fasting sugar | 1.17 (1.08–1.28) | <0.001 | 1.01 (0.91–1.13) | 0.726 |
| ALT/AST ratio | 2.56 (2.03–3.22) | <0.001 | 1.94 (1.49–2.53) | <0.001 |
| PLR | 1.17 (1.02–1.34) | 0.029 | 1.21 (1.03–1.43) | 0.018 |
| Apo-B | 1.52 (1.24–1.86) | <0.001 | 1.19 (0.93–1.54) | 0.160 |
| Biomarkers | ||||
| Lipoprotein(a) (µg/ml) | 0.77 (0.64–0.94) | 0.008 | 0.89 (0.71–1.11) | 0.303 |
| GAL-3 (ng/ml) | 1.44 (1.25–1.65) | <0.001 | 1.24 (1.05–1.46) | 0.010 |
Adjusted: The model was adjusted for sex, age, WHR, uric acid, TG, HDL, fasting sugar, ALT/AST ratio, PLR, Apo-B, lipoprotein(a), and GAL-3.
The ORs calculated for an interquartile range increase in WHR, laboratory data, and biomarkers.
ALT, alanine aminotransferase; apo-B, apolipoprotein B; AST, aspartate transaminase; CI, confidence interval; GAL-3, galectin 3; HDL, high-density lipoprotein cholesterol; OR, odds ratio; PLR, platelet-lymphocyte ratio; TG, triglyceride; WHR, waist-to-height ratio.